1. Introduction
===============

Rotaviruses cause gastroenteritis in almost all mammals and some birds \[[@B1-viruses-05-00792]\]. Group A, B and C rotaviruses are known to infect humans and animals; however, group A is responsible for gastroenteritis in children less than five years old \[[@B2-viruses-05-00792]\]. The common symptoms of this disease are diarrhea, fever and vomiting \[[@B3-viruses-05-00792]\]. Dehydration is a consequence of severe diarrhea that may cause infant death \[[@B2-viruses-05-00792],[@B3-viruses-05-00792]\]. Statistics reveal that rotaviruses cause approximately 453,000 child deaths per year worldwide, with the highest mortality rates primarily in developing countries \[[@B4-viruses-05-00792]\]. The rotavirus pathogenesis is related to the non-structural protein 4 (NSP4), which is a known enterotoxin \[[@B5-viruses-05-00792]\]. NSP4 induces an intracellular calcium imbalance, resulting in membrane instability and loss of water; the same effect would be present by phospholipase C-mediated inositol 1,4,5-trisphosphate production when NSP4 interacts with non-infected cells \[[@B2-viruses-05-00792],[@B6-viruses-05-00792],[@B7-viruses-05-00792],[@B8-viruses-05-00792]\].

NSP4 is a glycosylated protein of 175 amino acids and a molecular mass of 28 kDa in its mature form. This protein is characterized by three hydrophobic domains named H1 (residues 7−21), H2 (29−47) and H3 (67−85) and a coiled *α-*helical domain (95−137) \[[@B9-viruses-05-00792]\]. The NSP4 amino-terminal region (1−44) is located in the lumen of the endoplasmic reticulum, whereas its carboxy-terminal region (45--175) is in the cytoplasm and interacts with different proteins including VP6 and VP4 during rotavirus morphogenesis \[[@B10-viruses-05-00792],[@B11-viruses-05-00792],[@B12-viruses-05-00792]\]. NSP4 also interacts with some cellular proteins and extracellular matrix proteins \[[@B13-viruses-05-00792],[@B14-viruses-05-00792],[@B15-viruses-05-00792]\].

On the other hand, the NSP4 sequence analysis has revealed at least 14 genotypes named E1−E14 (for Enterotoxin). The human rotavirus genotypes are E1 (Wa-like), E2 (Kun-like) and E3 (AU-1), previously known as genotypes B, A and C, respectively \[[@B16-viruses-05-00792]\]. Information related to rotavirus infection and the role of NSP4 pathogenesis in humans has not been described in detail. Some reports indicate that changes in the sequence of NSP4, VP4 and VP7 are related with asymptomatic strains isolated from humans \[[@B17-viruses-05-00792],[@B18-viruses-05-00792]\], but amino acids variation in NSP4 has not always been associated with asymptomatic infections \[[@B19-viruses-05-00792],[@B20-viruses-05-00792],[@B21-viruses-05-00792]\]. In this study, we analyzed NSP4 of human rotavirus strains in Mexican children with different grades of gastroenteritis to determine the genotype, distribution and frequency of mutations in NSP4.

2. Results and Discussion
=========================

2.1. Rotavirus Positive Samples and Gastroenteritis Severity
------------------------------------------------------------

A total of 123 diarrheic feces collected from October 2004 to March 2005 from hospitalized children with gastroenteritis in Monterrey, Nuevo Leon, México, were analyzed to detect rotavirus. Of all the analyzed samples, sixty-six (53.7%) were positive for the presence of a rotavirus. This is a high percentage, because usually rotavirus infection is associated with 25−39% of hospitalizations for acute gastroenteritis \[[@B22-viruses-05-00792]\]. To further analyze the gastroenteritis severity, 16 of the 66 rotavirus positive samples were discarded due to incomplete data about the infected children or their symptoms. The remaining 50 gastroenteritis cases were considered in this study and the signs and symptoms of the rotavirus gastroenteritis were examined. Twenty-eight (56%) cases were male children and 22 (44%) were female children. Most of the rotavirus gastroenteritis cases (86%) were related to children under two years old, this is in agreement with previous reports on rotavirus infection \[[@B23-viruses-05-00792],[@B24-viruses-05-00792],[@B25-viruses-05-00792]\]. All the infected children included in this study had diarrhea within 1 to 4 days, 44 (88%) of them were vomiting and 35 (70%) had a fever. The results of the rotavirus gastroenteritis severity showed that 13 (26%) cases had a score ≤ 10, whereas 23 (46%) infections showed a score ≥ 11 and 14 (28%) cases had a score ≥ 15. Those scores were grouped as mild, moderate and severe gastroenteritis, respectively ([Table 1](#viruses-05-00792-t001){ref-type="table"}). Although some studies describe breastfeeding as an important factor to avoid severe gastroenteritis, we did not find a relationship between breastfeeding and the rotavirus gastroenteritis severity \[[@B26-viruses-05-00792],[@B27-viruses-05-00792],[@B28-viruses-05-00792]\]. This type of analysis of rotavirus regarding the prevalence and severity of the gastroenteritis may represent a basis to compare the epidemic seasons of the rotavirus before and after the introduction of the Rotarix® vaccine (GSK) \[[@B29-viruses-05-00792]\]. In this aspect, some studies have shown that this vaccine can diminish the cases of hospitalization by the rotavirus from 40 to 60% \[[@B30-viruses-05-00792],[@B31-viruses-05-00792],[@B32-viruses-05-00792]\]. Additionally, studies in Latin America have shown the efficiency of the vaccine to decrease the severity of the rotavirus gastroenteritis \[[@B33-viruses-05-00792],[@B34-viruses-05-00792]\].

2.2. The NSP4 Genotype
----------------------

NSP4 is a main factor of rotavirus pathogenesis \[[@B35-viruses-05-00792],[@B36-viruses-05-00792]\]. Therefore, in this study we have focused on the analysis of the NSP4 genotype and its sequence relationship with the rotavirus gastroenteritis severity. To amplify and identify the NSP4 genotype in all the rotavirus positive samples we used a combination of different primers that have been previously described \[[@B20-viruses-05-00792],[@B21-viruses-05-00792],[@B37-viruses-05-00792]\]. This was a useful strategy that identified 61 (92.4%) of the samples as NSP4 genotype E1. The predominant NSP4 genotype E1 identified in the studied area is commonly reported; some studies identified the E2 genotype as the second common genotype \[[@B38-viruses-05-00792],[@B39-viruses-05-00792],[@B40-viruses-05-00792],[@B41-viruses-05-00792]\]. Furthermore, others reported non-common NSP4 genotypes E3, E5, E6 and E13 in human rotavirus strains in Thailand, Brazil, Bangladesh and Kenya \[[@B42-viruses-05-00792],[@B43-viruses-05-00792],[@B44-viruses-05-00792],[@B45-viruses-05-00792],[@B46-viruses-05-00792]\].

2.3. The NSP4 Sequence Analysis
-------------------------------

According to the gastroenteritis severity analysis ([Table 1](#viruses-05-00792-t001){ref-type="table"}), the rotavirus positive samples were classified as mild (26%), moderate (46%) and severe (28%). Based on these results a stratified random sampling was done to select representative samples to the NSP4 sequence analysis, this selection included 4(31%) of 13 samples of mild cases, 7 (30%) of 23 cases of moderate and 5 (36%) of 14 severe cases. The analysis of the deduced amino acid sequences of NSP4 reported in this study showed three clusters inside the same genotype E1 ([Figure 1](#viruses-05-00792-f001){ref-type="fig"}). The NSP4 sequences MX04-29, MX05-58, MX05-126 reported here grouped in the cluster I; the samples MX05-48, MX05-71, MX05-88, MX05-137, and MX05-144 were in the cluster II and the samples MX04-27, MX04-28, MX05-36, MX05-51, MX05-64, MX05-68, MX05-107 and MX05-119 in the cluster III ([Table 3](#viruses-05-00792-t003){ref-type="table"}). Previous reports have shown the presence of at least two clusters within this genotype, and in some of them the clusters were related to the location or to the isolation date of the rotavirus strains, in this study we did not observed such relation \[[@B41-viruses-05-00792],[@B47-viruses-05-00792],[@B48-viruses-05-00792]\]. The NSP4 amino acids variations showed in the cluster I (amino acids AK in position 136-137 respectively) were related with rotavirus strains reported in Italy, China, Spain, United States of America (USA) and Russia (Accession number ACF77154, AFU36983, ADU55685, ADO78536 and ACY01369). The sequences in the cluster II share the same amino acid variations in the positions 141-145 with sequences from China, Russia, Thailand and USA (AAOO6852, ACQ99541, AFQ20926, ADO78564) and the cluster III shared common amino acid variations in aa 141,142, 144 and 145 with the strain Vanderbilt isolated in USA (AEB80046). Further analyses on NSP4 were performed using the amino acid frequency in each specific position in the protein. The analysis of 349 NSP4 sequences from the GenBank database showed that this protein is highly conserved in some specific domains ([Table 2](#viruses-05-00792-t002){ref-type="table"}). These conserved regions include the glycosylation sites (aa 8 and 18), the hydrophobic region H1, H2 and H3 (aa 7−21, 29−47 and 67−85), the transmembrane domain (aa 22−44) and the coiled *α-*helical domain (aa 97−137) where the frequency of the consensus amino acid in a specific position was 97.6 to 100%; however, the H3 domain showed an amino acid frequency of 88.9% for I72 and 87.4% for I76 ( [Table 2](#viruses-05-00792-t002){ref-type="table"}). Conversely, punctual variations in the NSP4 sequence fell in the VP4 binding site domain where the lowest amino acid frequency was at position 141 with a valine present for 58% of the studied sequences, and also the VP6 binding site where a serine at position 169 had a frequency of 56% ( [Table 2](#viruses-05-00792-t002){ref-type="table"}). Most of the amino acids variations in the NSP4 sequences reported were positioned in the carboxyl terminal region ([Table 3](#viruses-05-00792-t003){ref-type="table"}). However, the samples MX04-29, MX05-58 and MX05-126 showed punctual variations in conserved amino acids 111, 136 and 137 (85.7−92.8%), respectively ([Table 3](#viruses-05-00792-t003){ref-type="table"}). In addition, five of the NSP4 sequences reported in this study had an uncommon amino acid change at position 144, where a methionine was replaced by a valine. Usually methionine is present in this position in 97.9% of all the 349 NSP4 sequences analyzed ([Figure 1](#viruses-05-00792-f001){ref-type="fig"}), and thus this amino acid variation is unique in our sequences. Moreover, we did not find valine in this position in any other NSP4 genotype E1 sequence in the NCBI database. The replacement of a methionine may be not significant when it is replaced by another hydrophobic amino acid such as valine, because both amino acids can play a role in binding or recognition of hydrophobic ligands such as lipids. However, the sulfur atom in methionine can be involved in binding metals \[[@B49-viruses-05-00792]\] and NSP4 presents a metal binding domain between residues 114 and 135 \[[@B50-viruses-05-00792],[@B51-viruses-05-00792]\]; nevertheless, further analysis is required to explain the importance of the mutations in such conserved amino acid position within NSP4.

viruses-05-00792-t001_Table 1

###### 

Characteristics and symptoms of the children infected with the rotavirus and the analysis of the rotavirus severity score from slight to severe according to the Ruuska score \[[@B52-viruses-05-00792]\].

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gastroenteritis\   Gastroenteritis severity   Incidence   Breastfeeding   Sex   Age\*\     diarrhea episodes\* /24 h   Days with diarrhea\*   Vomiting episodes\* / 24hrs   Days of vomiting\*   
  severity\                                                                       (months)                                                                                                         
  (Ruuska score)                                                                                                                                                                                   
  ------------------ -------------------------- ----------- --------------- ----- ---------- --------------------------- ---------------------- ----------------------------- -------------------- -----
  ≤ 10               Mild                       13 (26%)    61.5%           6     7          8                           6.1                    2.4                           2.6                  1.0

  ≥ 11               Moderate                   23 (46%)    82.3%           15    8          12                          8.1                    3.1                           4.8                  2.7

  ≥ 15               Severe                     14 (28%)    71.4%           7     7          14                          10.4                   4.3                           9.3                  3.6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Average Data

viruses-05-00792-t002_Table 2

###### 

Consensus NSP4 sequence and the frequency of each amino acid in a specific position from residues 1 to 175. The analysis was obtained from 349 NSP4 sequences from the GenBank and is complemented with the description of some of the NSP4 domains. Abbreviations: **GS:** Glycosylation site, **H**: Hydrophobic domain.

  ---------------- ------------------------------ ------ ------ ------------ ------ ------ ------ ------ -------------- ------ ------------------------------ ---------------------------- ------ ----------------------- ------ ----- ---------------------------- ------ ------ ------ ------ ---------------------------- ------ ------ ------
                                                                                                                                                                                                                                                                                                Transmembrane site (22−44)                 
                                                                                                  GS1    H1 (aa 7−21)   GS2                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                           
  Consensus seq    M                              D      K      L            A      D      L      N      Y              T      L                              S                            V      I                       T      L     M                            N      D      T      L      H                            S      I      I
  Frequency %      100                            98.5   99.7   98           97.6   99.5   100    99.7   100            99.4   99.4                           92.7                         99.7   97.9                    98.2   99    100                          99.4   97.9   98.8   100    98.8                         98.8   100    98.8
  aa position      26                             27     28     29           30     31     32     33     34             35     36                             37                           38     39                      40     41    42                           43     44     45     46     47                           48     49     50
                                                                H2 (29−47)                                                                                                                                                                                                                                                                 
                   Transmembrane domain (22−44)                                                                                                                                                                                                                                                                                            
  Consensus seq.   Q                              D      P      G            M      A      Y      F      P              Y      I                              A                            S      V                       L      T     V                            L      F      T      L      H                            K      A      S
  Frequency %      97.6                           99.7   100    100          96.4   100    100    100    97.8           100    98.8                           100                          99.7   99.4                    100    100   994                          99.4   99.7   98.4   100    99.4                         99.4   100    99.4
  aa position      51                             52     53     54           55     56     57     58     59             60     61                             62                           63     64                      65     66    67                           68     69     70     71     72                           73     74     75
                                                                                                                                                                                                                                       H3 ( aa 67-85)                                                                                      
  Consensus seq.   I                              P      T      M            K      I      A      L      K              T      S                              K                            C      S                       Y      K     V                            I      K      Y      C      I                            V      T      I
  Frequency %      99.4                           99.4   99.1   99           99.7   99.4   100    99.4   96.6           99.4   100                            98.8                         99.1   100                     99.7   100   99.4                         97.9   99.1   98.5   98.8   88.9                         99.1   99.4   95.5
  aa position      76                             77     78     79           80     81     82     83     84             85     86                             87                           88     89                      90     91    92                           93     94     95     96     97                           98     99     100
                   H3 (67−85)                                                                                                  Alpha coiled Domain (95−137)                                                                                                                                                                                
  Consensus seq.   I                              N      T      L            L      K      L      A      G              Y      K                              E                            Q      V                       T      T     K                            D      E      I      E      Q                            Q      M      D
  Frequency %      87.4                           99.7   98.5   100          99.1   98.8   98.2   98.8   100            99.4   98.5                           100                          99.1   96.7                    98.8   98    99.1                         98.5   98.8   99.7   100    98.2                         99.7   99.7   99.1
  aa position      101                            102    103    104          105    106    107    108    109            110    111                            112                          113    114                     115    116   117                          118    119    120    121    122                          123    124    125
                   Alpha coiled Domain (95−137)                                                                                                                                                                                                                                                                                            
                                                                                                                                                              VP4 Binding site (112−148)                                                                                                                                                   
                                                                                                                                                                                                  Enterotoxin (114-135)                                                                                                                    
  Consensus seq.   R                              I      V      K            E      M      R      R      Q              L      E                              M                            I      D                       K      L     T                            T      R      E      I      E                            Q      V      E
  Frequency %      99.7                           98.8   99.1   99           99.7   99.4   99.7   100    98.5           99.7   93.4                           99.4                         99.7   99.1                    99.1   100   100                          98.8   99.1   99.7   99.7   99.7                         99.7   99.4   100
  aa position      126                            127    128    129          130    131    132    133    134            135    136                            137                          138    139                     140    141   142                          143    144    145    146    147                          148    149    150
                   Alpha coiled Domain (95−137)                                                                                                                                                                                                                                                                                            
                   VP4 Binding site (112−148)                                                                                                                                                                                                                                                                                              
                   Enterotoxin (114−135)                                                                                                                                                                                                                                                                                                   
  Consensus seq.   L                              L      K      R            I      H      D      N      L              I      T                              R                            P      V                       D      V     I                            D      M      S      K      E                            F      N      Q
  Frequency %      99.4                           100    99.7   99           99.7   92.8   99.1   78.6   100            90.7   93.4                           87.1                         78.4   88                      89.8   58    76                           99.4   97.9   64.3   99.1   99.1                         97.3   99.1   100
  aa position      151                            152    153    154          155    156    157    158    159            160    161                            162                          163    164                     165    166   167                          168    169    170    171    172                          173    174    175
                                                                                                                                                                                                                                       VP6 Binding site (167−175)                                                                          
  Consensus seq.   K                              N      I      K            T      L      D      E      W              E      S                              G                            K      N                       P      Y     E                            P      S      E      V      T                            A      S      M
  Frequency %      98.8                           99.7   94     93           100    99.7   98.2   99.1   100            95.8   77                             99.7                         97.6   99.1                    100    100   99.1                         100    56     99.1   99.4   99.7                         100    98.8   100
  ---------------- ------------------------------ ------ ------ ------------ ------ ------ ------ ------ -------------- ------ ------------------------------ ---------------------------- ------ ----------------------- ------ ----- ---------------------------- ------ ------ ------ ------ ---------------------------- ------ ------ ------

viruses-05-00792-t003_Table 3

###### 

Sequence analysis of the amino acid variations in the NSP4 protein from rotavirus strains reported in this study.

  NSP4 Sequence               Severity scores   Cluster    Amino acid variability and distribution                                                                                                                                                                
  --------------------------- ----------------- ---------- ----------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -------- -------- -------- --------- --------- -------- --------- -- --
  MX04-29                     16                I                                                                                     N                     A          K                                                                                          
  MX05-58                     14                I                                                                                     D                     A          K                                                                                          
  MX05-126                    16                I                                                    V                                D                     A          K                                                                                          
  MX05-48                     8                 II         V                                                    H                                                                 T                            T        N         I                               
  MX05-144                    13                II         V                                                                                                                      T                            T        N         I                               
  MX05-137                    15                II         V                                                                                                                      T                            T        N         I                               
  MX05-88                     16                II         V                                                                                                                      T                            T        N         I                               
  MX05-71                     0                 II         V                                                                                                                      T                            T        N         M                               
  MX04-27                     11                III                                                                                                                               S          V        V        T                  I                               
  MX04-28                     14                III                                                                                                                               S          V        V        T                  I                               
  MX05-36                     8                 III                                                                                                                               S          V        V        T                  I                               
  MX05-51                     14                III                                                                                              N                                S          V        V        T                  I         I                     
  MX05-64                     12                III                                                                                                                               S          V        V        T                  I                               
  MX05-68                     8                 III                                                                        G                                                      S          V        V        T                  I                               
  MX05-107                    14                III                                                                                                                               S          V        V        T                  I                               
  MX05-119                    15                III                                                                                                                               S          V        V        T        N         I                               
  **Consensus amino acids**   **I**             **N**      **Y**                                     **E**      **E**      **D**      **T**      **R**      **V**      **I**      **M**      **S**    **S**    **S**    **T**     **A**     **S**    **M**        
  **Frequency %**             **86**            **99.7**   **99.4**                                  **99.1**   **89.4**   **99.4**   **92.8**   **85.7**   **56.2**   **75.9**   **99.4**   **61**   **76**   **56**   **100**   **100**   **99**   **100**      

\* **H3:**hydrophobic region 3; **TD:** Tetramerization Domain; ACD: Alpha Coiled Coil Domain **E:**Enterotoxin Domain; **VP4:**VP4 Binding site domain; **VP6:**VP6 binding site domain

![Phylogenetic analysis of the deduced amino acid NSP4 sequences reported in this study and other NSP4 genotypes previously reported in the NCBI. The phylogenetic tree was constructed based on the neighbor-joining method. The bootstrap consensus tree inferred from 500 replicates is taken to represent the evolutionary history of the taxa analyzed. The evolutionary distances were computed using the p-distance method and are in the units of the number of amino acid differences per site. Evolutionary analyses were conducted in MEGA5 package \[[@B54-viruses-05-00792]\]. Accession number of the sequences reported in this study in the GenBank: MX04-28: JX458969, MX04-29: JX458970, MX04-27:JX458971, MX05-51:JX458972, MX05-144: JX458973, MX05-58: JX458974, MX05-68: JX458975, MX05-71:JX458976, MX05-88:JX458977, MX05-119:JX458978, MX05-107: JX458982, MX05-126: JX458983, MX05-137: JX458984.](viruses-05-00792-g001){#viruses-05-00792-f001}

3. Experimental Section
=======================

3.1. Samples Recollection and Gastroenteritis Severity Score
------------------------------------------------------------

A total of 123 stool samples were collected from hospitalized children with gastroenteritis in Monterrey, Nuevo León, México, from October 2004 to March 2005. The inclusion criteria were the age of the child, up to five years old, and the hospitalization for nonbacterial gastroenteritis. Diarrhea, vomiting and fever were used as registered symptoms to calculate the gastroenteritis severity, and formed the basis of the Ruuska score \[[@B52-viruses-05-00792]\].

3.2. Extraction of Rotavirus RNA.
---------------------------------

The feces samples were used to isolate, purify and detect the rotavirus RNA genome by TRI Reagent® (Molecular Research Center, Cincinnati, OH) as suggested the by supplier. The viral RNA was loaded onto a 10% polyacrylamide gel under native conditions, and then stained by a silver-staining procedure. A sample was considered positive to the rotavirus when a characteristic double-stranded RNA genome was observed in the gel \[[@B53-viruses-05-00792]\].

3.3. NSP4 Genotype Identification and Sequence
----------------------------------------------

RNA positive samples for the rotavirus were retro transcribed and amplified by PCR to isolate the NSP4 gene using the primers Beg16-End722 or NSP41F-NSP42R \[[@B20-viruses-05-00792],[@B21-viruses-05-00792]\]; although in several experiments, combinations of both primer pairs were required to achieve amplification. NSP4 genotype identification was performed by a multiplex-seminested PCR, with 10END722 or NSP42R as the external primers and Wa, Kun or RRV as the internal primers, which corresponds to genotypes E1, E2 and E3, respectively \[[@B37-viruses-05-00792]\]. Samples of the amplified NSP4 gene were cloned using the pGEM-T vector (Promega Inc, Madison, WI) according to the manufacturer´s instructions. The plasmid with the NSP4 insert was purified by the Wizard SV Minipreps kit (Promega Inc, Madison, WI) and sequenced by the dideoxynucleotide chain termination method, using an ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (PE Applied Biosystems, Whashington, DC). The DNA sequence was confirmed by sequencing both DNA strands of each of the different clones using the pUCM13 sense and antisense standard primers. The resulting sequences were analyzed with MEGA 5.0 and compared with other sequences reported in the GenBank data base; the phylogenetic tree was determined by the Neighbor joining method \[[@B54-viruses-05-00792]\]. The GenBank accession numbers of NSP4 sequences used in sequence analysis were AB361285, AB008233, AB008237, AB213391, AB326290, AB326294, AB326963, AB361282, AF170830, AF260930, AY159640, AY159642, AY353740, AY353800, DQ909069, DQ909070, EF033202, EF033203, EF672575, EU679377, EU679382, U42628, U83798, AAO06852, AAT48079, AB008229 - AB008231, AB008234-AB008236, AB008238-AB008245, AB008247-AB008257, AB008259 - AB008263, AB022772, AB043026, AB043069-AB043078, AB196491, AB196492, AB196958, AB196959, AB211987-AB213392, AB232699, AB269688, AB303218, AB326286-AB326289, AB326293, AB326295, AB326297, AB326334, AB326336, AB326337, AB326347, AB326348, AB326962, AB326966, AB326969, AB326971, AB361276, AB361281, AB361284, AB361286-AB361288, ABK62862, ABU49806, ACF77153, ACF77154, ACJ54826, ACJ66758, ACJ66769, ACL80635, ACL80638, ACQ99541, ACY01369, ACY01381, ACZ51671, ADA70484, ADK46705, ADK46715, ADO78533, ADO78536, ADO78564, AEB79485, AEB79550, AEK69633, AET43468, AF161810-AF161815, AF170831-AF170833, AF173179, AF173181-AF173208, AF173211 - AF173214, AF174300 - AF174302, AF260928, AF260929, AF284776-AF284778, AF469676 - AF469679, AF506016, AF541921, AFJ68184, AFJ68397, AFK27432, AJ236757 - AJ236770, AJ236772 - AJ236774, AJ236778 - AJ236782, AJ400634, AY159630 - AY159632, AY159634 - AY159639, AY159641, AY159643, AY159644 - AY159647, AY353727, AY353728, AY353730 - AY353739, AY353741 - AY353746, AY353753 - AY353765, AY353767 - AY353790, AY353792 - AY353805, AY601540 - AY601544, AY629562, BAD84188, BAF97950, CAB36938, D88830, DQ146647, DQ146658, DQ146669, DQ146680, DQ189233 - DQ189237, DQ189240, DQ299876, DQ339147 - DQ339151, DQ490543, DQ492678, DQ525182 - DQ525188, EF011980, EF033204, EF059918, EF059919, EF059924, EF159574, EU679378 - EU679380, GAU78558, Q9YJN7, U59108, U59110.

4. Conclusions
==============

The presence of intra-genotypic clusters and punctual amino acid variations in the NSP4 genotype E1 may indicate that NSP4 mutates mainly via accumulation of single point mutations. Since most of the variations in NSP4 fell in the carboxylic terminal region, especially in the VP4 binding site segment, it is important to consider that NSP4 is involved in morphogenesis and pathogenesis activities. Further analysis of NSP4 in the VP4 and VP6 binding site segment should be studied, especially with respect to structural conformational changes caused by amino acid variations. NSP4 is an important factor in rotavirus pathogenesis, and in this study an analysis examining the amino acid variations in the sequence and the gastroenteritis severity score was performed. The results failed to show a relationship between punctual variations in NSP4 and the severity of rotavirus gastroenteritis. The study of the NSP4 protein and its interaction with other viral proteins may aid our understanding of the pathogenesis of the rotavirus.
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